PURE Bioscience Net Income

The latest net income for PURE is $-2.2M as of April 2026. That compares with $-2.8M in the prior-year period — up 21.9% year over year. That is below the sector sector average of $89M. Investors often review this figure alongside PURE Bioscience's historical trend and sector peers before judging valuation or financial health.

Over the past year, PURE's net income moved from $-2.8M to $-2.2M — a 21.9% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in PURE Bioscience's operating scale or balance-sheet position.

Against its sector companies, PURE currently prints $-2.2M for net income, while the sector average sits near $89M. That is roughly 102.5% below the sector mean. Large gaps often invite a closer look at PURE Bioscience's growth, margins, and balance sheet.

A net income figure of $-2.2M for PURE is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The sector average is about $89M. Explore the charts below for those layers of context.

After noting PURE's net income ($-2.2M), review year-over-year change from $-2.8M, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.